EP3601288A1 - Tétrahydrofolates isomériquement purs marqués au 18f - Google Patents

Tétrahydrofolates isomériquement purs marqués au 18f

Info

Publication number
EP3601288A1
EP3601288A1 EP18710887.3A EP18710887A EP3601288A1 EP 3601288 A1 EP3601288 A1 EP 3601288A1 EP 18710887 A EP18710887 A EP 18710887A EP 3601288 A1 EP3601288 A1 EP 3601288A1
Authority
EP
European Patent Office
Prior art keywords
compound
diagnostic imaging
folate
labelled
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP18710887.3A
Other languages
German (de)
English (en)
Other versions
EP3601288B1 (fr
Inventor
Rudolf Moser
Viola Groehn
Cristina MUELLER
Roger Schibli
Simon Ametamey
Silvan BOSS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to PL18710887T priority Critical patent/PL3601288T3/pl
Publication of EP3601288A1 publication Critical patent/EP3601288A1/fr
Application granted granted Critical
Publication of EP3601288B1 publication Critical patent/EP3601288B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Definitions

  • the present invention is directed towards the use of isomerically pure 18 F-labelled (6S)- or (6R)-tetrahydro folate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18 F-labelled N-heterocycle, in diagnosis of a cell or population of cells expressing a fo late-receptor and monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof.
  • Receptor-specific targeting for delivery of effector moieties such as diagnostic or therapeutic agents is a widely researched field and has led to the development of non-invasive diagnostic and/or therapeutic medical applications.
  • radioactive materials emitting electromagnetic radiations such as ⁇ -rays or particle emitting radiation
  • selective localization of these radioactive materials in targeted cells or tissues is required to achieve either high signal intensity for visualization of specific tissues, assessing a disease and/or monitoring effects of therapeutic treatments, or high radiation dose, for delivering adequate doses of ionizing radiation to a specified diseased site, without the risk of radiation injury/radiotoxicity in other e.g. healthy tissues.
  • the FR-a represents an optimal target for tumor imaging since it is overexpressed on various epithelial cancer types such as ovarian, uterus, kidney, breast, lung and colon-rectum cancer, but only limited expression in healthy tissues including the kidney, choroid plexus, salivary glands, lung and placenta (Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., and Leamon, C. P.
  • Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 338, 284-293.
  • folic-acid based radiotracers also bind the FR- ⁇ isoform, which is upregulated on activated macrophages involved in inflammation, with similar high affinity (Nakashima-Matsushita, N., Homma, T., Yu, S., Matsuda, T., Sunahara, N., Nakamura, T., Tsukano, M., Ratnam, M., and Matsuyama, T. (1999) Selective expression of folate receptor ⁇ and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 42, 1609-1616; Paulos, C. M., Turk, M.
  • Betzel et al recently reported a promising fluorine- 18 labeled folic acid derivative designated 3'-aza-2'-[ 18 F]fluorofolic acid for imaging FR-positive cancer tissue (Betzel, T., Muller, C, Groehn, V., Muller, A., Reber, J., Fischer, C. R., Kramer, S. D., Schibli, R., and Ametamey, S. M. (2013) Radiosynthesis and Preclinical Evaluation of 3 ' -Aza-2 ' -[ 18 F]fluorofolic Acid: A Novel PET Radiotracer for Folate Receptor Targeting. Bioconjug. Chem. 24, 205-214.)
  • FR-alpha-positive tissue can be achieved with isomerically pure 18 F-labelled tetrahydro folate derivatives such as the physiological (6R)-form of 3'-aza-2'-[ 18 F]fluoro-5-methyltetrahydrofolate.
  • 5- methyltetrahydrofolate which is a derivative of the reduced physiological folate form binds to the FR with high affinity and exhibits a 50-fold higher selectivity for FR-alpha than the respective oxidized folic acid derivative.
  • a PET tracer that selectively targets tumor associated FR-alpha and not FR-beta at inflammatory sites containing FR-beta is providing significant sensitivity and specificity. Having deduced from picture of an unspecific PET tracer what is coming from a PET tracer that selectively targets tumor associated FR-alpha one can gain information on inflammatory sites containing FR-beta.
  • the present invention is directed in a first aspect to the use of isomerically pure F-labelled tetrahydro folate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18 F-labelled N-heterocycle in diagnostic imaging of a cell or population of cells expressing a fo late-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof.
  • the F-labelled tetrahydrofolate radiopharmaceuticals wherein the phenyl group within the folate structure, has been replaced by an 18 F-labelled N-heterocycle are in their isomerically pure (6S)- or (6R)-form.
  • the isomerically pure F-labelled (6S)- or (6R)-tetrahydro folate radiopharmaceuticals wherein the phenyl group within the folate structure, has been replaced by an 18 F-labelled N-heterocycle is an isomerically pure 18 F-labelled 5-methyl-(6S)- tetrahydrofolate or an isomerically pure F-labelled 5 -methyl-(6R)-tetrahydro folate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18 F-labelled N-heterocycle.
  • the isomerically pure F-labelled (6S)- or (6R)-tetrahydro folate radiopharmaceutical wherein the phenyl group within the folate structure, has been replaced by an 18 F-labelled N-heterocycle is an isomerically pure 3'-aza-2'-[ 18 F]f uoro-5-methyl-(6S)- tetrahydro folate or an isomerically pure 3'-aza-2'-[ 18 F]f uoro-5-methyl-(6R)-tetrahydrofolate.
  • a compound of formula la or lb for use in diagnostic imaging of a cell or population of cells expressing a fo late-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof
  • Ri, R2 are independently of each other H or straight chain or branched C1-C6 alkyl, and R3, R4 are independently of each other H, formyl, or methyl, or a pharmaceutically acceptable salt thereof.
  • Ri, R2 are independently of each other H or straight chain or branched C1-C6 alkyl, and R3 is methyl, and R4 is H, or a pharmaceutically acceptable salt thereof.
  • the present invention is directed towards a compound having formulas Ila or lib for use in diagnostic imaging of a cell or population of cells expressing a fo late-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof
  • Ri, R-2 are independently of each other H, or CI -CI 2 alkyl, or a pharmaceutically acceptable salt thereof.
  • the present invention is directed towards a compound having formulas Ilia or Illb for use in diagnostic imaging of a cell or population of cells expressing a fo late-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof
  • the isomerically pure F-labelled (6S)- or (6R)-tetrahydro folate radiopharmaceutical wherein the phenyl group within the folate structure, has been replaced by an 18 F-labelled N-heterocycle is directed to alkali or alkaline earth metal salts, preferably sodium, potassium, magnesium or calcium salts.
  • the present invention is directed to the use of isomerically pure
  • compositions thereof) in monitoring cancer or inflammatory and autoimmune disease therapy in a subject comprising the steps of (i) administering to a subject in need isomerically pure F-labelled (6S)- or (6R)-tetrahydro folate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18 F-labelled
  • N-heterocycle in a diagnostic imaging amount in combination with a therapeutically active and (ii) performing diagnostic imaging using PET by detecting a signal from said at least one compound to follow the course of cancer or inflammatory and autoimmune disease therapy.
  • the present invention is directed to the use of isomerically pure
  • compositions thereof) in diagnostic imaging of a cell or population of cells expressing a fo late-receptor in diagnostic imaging of a cell or population of cells expressing a fo late-receptor.
  • Figure 1 Chiral HPLC chromatograms of the precursor N 2 -acetyl-3'-aza-2'-chloro- 5-methyltetrahydrofolate-di-tert-butylester 6S-2 and 6R-2 (A) and the protected reference N 2 -acetyl-3'-aza-2'-fluoro-5-methyltetrahydrofolate-di-tert-butylester 6S-2 and 6R-2 (B).
  • Figure 2 CD spectra of 6S- and 6i?-5-MTHF (A) and 6R-1 and 6S-1 (B) measuring from 400 nm to 200 nm.
  • Figure 3 Overlay of the CD spectra of 6S-5-MTHF and 6S-3'-aza-2'-fluoro-5-MTHF (A) and 6i?-5-MTHF and 6R-3'-aza-2'-fiuoro-5-MTHF (B).
  • FIG. 4 Radio-UPLC chromatograms of reference radiotracer 65 * /6i?-[ 18 F]l (A), liver sample (B), blood plasma (C) and urine sample (D) 60 min after injection of 6S/6R-[ 18 F]1. Retention time is indicated above the peak.
  • Figure 5 Radioactivity accumulation of 6i?-3'-aza-2'-[ 18 F]fluoro-5-MTHF (A) and 65 * -3'-aza- 2'-[ 18 F]fluoro-5-MTHF (B) in some selected tissues at 30, 60 and 90 min p.i..
  • Figure 6 Comparison of the tumor-to-kidney (A), tumor-to-blood (B) and tumor-to-liver (C) ratios of 6i?-[ 18 F]l and 6S-[ 18 F]1.
  • Figure 7 Tissue distribution profile at 30, 60 and 90 min after injection of 18 F-6i?-5Me- AzaTHF.
  • Figure 8 Tissue distribution profile at 30, 60 and 90 min after injection of 18 F-6S-5Me- AzaTHF.
  • Figure 9 Comparison of the tissue distribution profile of 18 F-6i?-5Me-AzaTHF ( >i?-form) and the 18 F-6S-5Me-AzaTHF ( S-form).
  • Figure 10 Comparison of the tumor-to-blood ratios of 18 F-6i?-5Me-AzaTHF ( >i?-form) and the 18 F-6S-5Me-AzaTHF ( S-form).
  • Figure 11 Comparison of the tumor-to-liver ratios of 18 F-6i?-5Me-AzaTHF ( >i?-form) and the 18 F-6S-5Me-AzaTHF ( S-forai).
  • Figure 12 Comparison of the tumor-to-kidney ratios of 18 F-6i?-5Me-AzaTHF ( >i?-form) and the 18 F-6S-5Me-AzaTHF ( S-form).
  • FIG. 13 PET/CT scans of a KB tumor-bearing mouse 1 h, 2 h and 3 h after injection of 18 F-6R-Aza-5MeTHF.
  • Tu tumor xenografts
  • Li liver
  • Ki kidney
  • white arrow gall bladder
  • FIG 14 PET/CT scans of a KB tumor-bearing mouse 1 h, 2 h and 3 h after injection of 18 F-6Pv-Aza-5MeTHF.
  • Tu tumor xenografts
  • Li liver
  • Ki kidney
  • white arrow gall bladder
  • FIG. 16 PET/CT scans of a KB tumor-bearing mouse 1 h, 2 h and 3 h after injection of 18 F-6S-Aza-5MeTHF.
  • Tu tumor xenografts
  • Ki kidney
  • SG salivary glands
  • white arrow gall bladder
  • green arrow choroid plexus
  • FIG. 17 PET/CT scans of a KB tumor-bearing mouse 1 h, 2 h and 3 h after injection of 18 F-6S-Aza-5MeTHF.
  • Tu tumor xenografts
  • Ki kidney
  • SG salivary glands
  • white arrow gall bladder
  • green arrow choroid plexus
  • Figure 22 Uptake and internalization of 6i?-[ 18 F]l (A) or 6,S-[ 18 F]1 (B) with FR-positive KB cells incubating at 37 °C for 1, 2, or 3 h. Blocking studies were performed using an excess of folic acid.
  • Figure 23 Total uptake and internalization of 18F-AzaFol, using RT16 (FR-a) and D4 (FR- ⁇ ) cell lines.
  • Figure 24 Total uptake and internalization of 6i?-3-aza-2- 18 F-5-MTHF using RT16 (FR-a) and D4 (FR- ⁇ ) cell lines.
  • Figure 25 Total uptake and internalization of 65'-3-aza-2- 18 F-5-MTHF using RT16 (FR-a) and D4 (FR- ⁇ ) cell lines.
  • Figure 26 Structure and stereochemical denomination of reduced 18 F-folates
  • the present invention is directed in a first aspect to the use of isomerically pure F-labelled tetrahydro folate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18 F-labelled N-heterocycle in diagnostic imaging of a cell or population of cells expressing a fo late-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof.
  • THF Tetrahydrofolate
  • 5-methyi-THF distinguish themselves from their oxidized form, such as folic acid, by the addit ional chira! centre at C6, which leads to the isomeric (6S)- and (6R)-forms.
  • the a-carbon of the glutamic acid moiety is in both the folic acid and the tetrahydro folates as defined herein in the naturally occurring configuration.
  • the compounds for use according to the present invention are preferably in a isomerically pure form.
  • Tetrahydro folates as used herein comprise the acid form o the tetrahydro folate and also the respective ester forms.
  • radiopharmaceuticals of general formula la or lb or a pharmaceutically acceptable salt thereof for use in diagnostic imaging of a cell or population of cells expressing a fo late-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof
  • Ri, R2 are independently of each other H or straight chain or branched C1-C6 alkyl
  • R3, R4 are independently of each other H, formyl, or methyl.
  • alkyl when used singly or in combination, refers to straight chain or branched alkyl groups containing in the indicted number of C-atoms, typically containing 1 to 6, preferably 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, t-butyl and the like.
  • Pharmaceutically acceptable salts can be alkali or alkaline earth metal salts, preferably sodium, potassium, magnesium or calcium salts or can also be acidic salts, such as sulfate or sulfonate salts, preferably sulfate salts.
  • the present invention is directed towards compounds of formula Ila or lib or a pharmaceutically acceptable salt thereof for use in diagnostic imaging of a cell or population of cells expressing a fo late-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof,
  • Ri , R2 are independently of each other H, or C1-C12 alkyl.
  • the present invention is directed towards a compound formulas Ilia or 11 lb or a pharmaceutically acceptable salt thereof for use in diagnostic imaging of a cell or population of cells expressing a fo late-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof
  • F-labelled tetrahydro folate radiopharmaceuticals wherein the phenyl group within the folate structure, has been replaced by an 18 F-labelled N-heterocycle, is highly surprising and could not be expected.
  • the present invention is directed towards a method for diagnostic imaging of a cell or population of cells expressing a fo late-receptor, said method comprising the steps of administering at least one compound according to formula la, lb, Ila, lib, Ilia, or Illb in a diagnostic imaging amount, and obtaining a diagnostic image of said cell or population of cells.
  • the present invention provides uses of isomerically pure F-labelled tetrahydro folate radiopharmaceuticals for convenient and effective administration to a subject in need for diagnostic imaging.
  • the present invention provides a method for diagnostic imaging of a cell or population of cells expressing a fo late-receptor, said method comprising the steps of administering at least one isomerically pure F-labelled tetrahydro folate radiopharmaceutical of the invention in a diagnostic imaging amount, and obtaining a diagnostic image of said cell or population of cells.
  • Such imaging may be performed on a cell or population of cells expressing a fo late-receptor in vitro or ex vivo (biopsies) or in vivo.
  • Typical cells or population of cells overexpressing the folate receptor-a are epithelial cancer types such as ovarian, uterus, kidney, breast, lung and colon-rectum cancer.
  • the present invention provides a method for in vitro detection of a cell expressing the folate receptor in a tissue sample which includes contacting said tissue sample with at least one isomerically pure F-labelled tetrahydro folate radiopharmaceutical of the invention in effective amounts and for sufficient time and conditions to al-low binding to occur and detecting such binding by PET imaging.
  • the present invention provides uses of isomerically pure F-labelled tetrahydro folate radiopharmaceuticals of the present invention for convenient and effective administration to a subject in need for diagnostic imaging or monitoring of cancer therapy or therapy of inflammatory and autoimmune diseases.
  • the present invention provides a method for simultaneous diagnosis and therapy, comprising the steps of administering to a subject in need thereof at least one isomerically pure F-labelled tetrahydro folate radiopharmaceutical of the present invention in a diagnostically effective amount in combination with a therapeutically active, and obtaining a diagnostic image of said tissues to follow the course of treatment.
  • the subject of the methods of the present invention is preferably a mammal, such as an animal or a human, preferably a human.
  • the dosage depends on the nature of the effect desired, such as the form of diagnosis or therapy, on the kind and frequency of treatment, on the diagnostic instrumentation, on the form of application of the preparation, and on the age, weight, nutrition and condition of the recipient, kind of concurrent treatment, if any.
  • the most preferred dosage can be tailored to the individual subject, as is understood and determinable by one of skill in the art, without undue experimentation. This typically involves adjustment of a standard dose, e.g., reduction of the dose if the patient has a low body weight.
  • Treatment can commence with a smaller amount, below the optimum amount, which can be increased in order to achieve the optimum effect.
  • the imaging procedure in the PET scanner takes place from within minutes to 2-4 hours after administration of the radiotracer.
  • the schedule depends on the imaging target and kinetics of the radiotracer as well as the desired information.
  • the preferred route of administration of the isomerically pure F-labelled tetrahydro folate radiopharmaceuticals of the present invention is by parenterally e.g. by intravenous injection.
  • the suitable forms for injection include sterile aqueous solutions or dispersions of the above mentioned isomerically pure F-labelled tetrahydro folate radiopharmaceuticals of the present invention.
  • the radiopharmaceutical will be formulated in physiological buffer solutions.
  • Isomerically pure F-labelled tetrahydro folate radiopharmaceuticals undergo sterilization by any art recognized technique, including but not limited to, addition of antibacterial of antifungal agents, for example, paraben, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. Preferably they undergo a sterile filtration before administration eliminating the need of additional sterilisation agents.
  • a preferred unit dosage is from about 0.01 ml to about 10 ml.
  • imaging of the organ or tumor in vivo can take place, if desired, from within minutes to 2 to 4 hours after the radiolabeled reagent has been administered to a subject to allow a sufficient amount of the administered dose to accumulate in the targeted area of choice.
  • Isomerically pure F-labelled tetrahydro folate radiopharmaceuticals of the invention may also be used for in vitro detection of a cell expressing the folate receptor in a tissue biopsy taken from a subject.
  • the present invention provides a method for in vitro detection of a cell expressing the folate receptor, e.g. a tumor cell, in a tissue sample which includes contacting said tissue sample with isomerically pure F-labelled tetrahydro folate radiopharmaceuticals of the present invention in effective amounts and for sufficient time and conditions to allow binding to occur and detecting such binding by imaging techniques.
  • Samples can be collected by procedures known to the skilled person, e.g., by collecting a tissue biopsy or a body fluid, by aspirating for tracheal or pulmonary samples and the like.
  • Tissue samples to be tested include any tissue suspected to contain a cell expressing a folate receptor, such as tumor cells, epithelial cells, kidneys, gastrointestinal or the hepatobiliary system, and others. Samples can be sectioned, e.g., with a microtome, to facilitate microscopic examination and observation. Samples can also be fixed with an appropriate fixative either before or after incubation with one of the F-labelled tetrahydro folate radiopharmaceuticals of the present invention to improve the histological quality of sample tissues.
  • Time and conditions sufficient for binding of isomerically pure F-labelled tetrahydro folate radiopharmaceuticals of the present invention to a folate receptor on the cell include standard tissue culture conditions, i.e. samples can be cultured in vitro and incubated with one of the complexes or compositions of the present invention in physiological media. Such conditions are well known to the skilled person. Alternatively, samples can be fixed and then incubated with isomerically pure F-labelled tetrahydro folate radiopharmaceuticals of the present invention in an isotonic or physiological buffer.
  • Reagents and solvents were purchased from Sigma-Aldrich Chemie GmbH, Acros Organis and used without purification.
  • the building blocks were bought from ABCR-Chemicals, Apollo Scientific, Fluka-Chemie and Merck & Cie (Schaffhausen, Switzerland).
  • 6i?-10-formyl-5-methyltetrahydropteroic acid (6i?-10-formyl-5-MTHP) was provided by Merck & Cie (Schaffhausen, Switzerland). Quality control of these building blocks was performed with 'H-NMR, 13 C-NMR, cosygp and HR-MS.
  • the solvents for conducting the flash chromatography, transferring reaction mixtures, extraction and washing processes were directly purchased from the fuel depot from ETH.
  • High-resolution mass spectra were recorded by the MS service of the Laboratorium fur Organische Chemie at ETH Zurich on a Varian IonSpec Ultima MALDI-FT-ICR or a Bruker Daltonics Ultra-Flex II MALDI-TOF.
  • Trans-2-[3-(4-tert-Butylphenyl)-2-methyl- 2-propenyli-dene]malononitrile (DCTB) and 3-hydroxypyridine-2-carboxylic acid (3 -HP A) served as matrices for MALDI mass spectrometry.
  • ESI mass spectra were recorded with a Bruker FTMS 4.7 T BioAPEXII (ESI).
  • Preparative HPLC was performed with a Merck-Hitachi system, equipped with a D7000 interface, L-7400 UV detector, and a L-7150 pump, using an Ultimate XB-C18 column (150 x 21.2 mm, 5 ⁇ ) (Ultisil, Welch Materials) at a flow rate of 15 mL/min (280 nm).
  • Analytical HPLC was performed with a Merck-Hitachi system, equipped with a D-7000 interface, L-7400 UV detector, and a L-7100 pump, using a sunfire C18 column (4.6 x 150 mm, 5 ⁇ ). If not described otherwise, reaction control was performed via analytical HPLC using 10 mM NH4HCO3 solution (solvent A) and MeCN (solvent B) and the following gradient: 0-30 min: 100 - 60 % A, 30-35 min: 60% A, 35-36 min: 60 - 100% A, 36-40 min: 100% A at a flow rate of 1 mL/min and at 280 nm.
  • Analytical radio-HPLC was performed on an Agilent 1100 series HPLC system, equipped with a 100 ⁇ - ⁇ and a GabiStar radiodetector (Raytest).
  • the analytical Phenomenex Gemini C18 column (4.6 x 250 mm, 5 ⁇ , 110 A, no precolumn) was used at a flow rate 1 mL/min at 280 nm.
  • Analytical HPLC was performed with 10 mM NH4HCO3 (solvent A) and MeCN (solvent B) as solvent system with the gradient as follows: 0-20 min: 95 - 60%> A, 20- 25 min: 60% A, 25-26 min: 60 - 95% A, 26-30 min: 95% A.
  • Reaction control was performed with a radio ultra-performance liquid chromatography (radio- UPLC, Waters) using an Acquity UPLC BEH CI 8 column (2.1 x 50 mm, 1.7 ⁇ , Waters) and an attached coincidence detector (FlowStar LB513, Berthold) and with a 10 mM
  • No-carrier-added [ 18 F]fluoride was obtained by irradiation of a liquid target, filled with isotopically enriched [ 18 0]H 2 0 (930 ⁇ ,, 97%, Cambridge Isotope Laboratories) by an
  • Biodistribution studies were performed 2 weeks after cell inoculation.
  • the 18 F-folate radiotracers ( ⁇ 5 MBq/mouse) were injected in a volume of 100 into a lateral tail vein.
  • the animals were sacrificed at 30 min, 60 min and 90 min after administration of radiotracers.
  • Selected tissues and organs were collected, weighed, and radioactivity was measured using a ⁇ -counter.
  • the results were listed as a percentage of the injected radioactivity per gram of tissue mass (% IA/g), using counts of a defined volume of the original injection solution measured at the same time resulting in decay corrected values.
  • mice were prepared the same way as for biodistribution studies.
  • a bench-top preclinical PET scanner (Genisys 8 , Sofie Biosciences, U.S. and Perkin Elmer, U.S.) was employed for the PET/CT scans of the mice.
  • the energy window was set to 150-650 keV.
  • Mice were injected intravenously with the 18F-radiotracers ( ⁇ 5 MBq in 100 During the scans, which lasted for 10 min, the mice were anesthetized using a mixture of isoflurane and oxygen. Scans were performed at lh, 2 h and 3 h after injection of the 18 F-radiotracers using G8 acquisition software (version 2.0.0.10).
  • the images were reconstructed with maximum- likelihood expectation maximization (MLEM).
  • MLEM maximum- likelihood expectation maximization
  • Example 1 Synthesis and separation (by chiral HPLC) of 6S- and 6R-7V 2 -Acetyl-3'- Aza-2'-Fluoro/2'-Chloro-5-Methyltetrahydrofolate Di-73 ⁇ 4rf-Butylester
  • N 2 -Acetyl-3'-aza-2'-chloro-folic acid-di-tert-butylester and N 2 -Acetyl-3'-aza-2'-fluoro-folic acid-di-tert-butylester was achieved according to WO 2013/167653.
  • Chiral separation of the two diastereoisomers of both mixtures into the compounds as disclosed in Scheme lb was achieved using the Reprosil 100 Chiral-NR HPLC column running on normal phase
  • 6R-2 (7.00 mg, 1 1.1 nmoL) was dissolved in acetone (200 pL) and 4M HC1 (500 pL) and stirred for 1 h at 70 °C (Scheme lb). After completion of the reaction, the solution was neutralized with 4M NaOH and the product was purified by semipreparative HPLC.
  • 6S-2 (8.00 mg, 12.6 ⁇ ) was dissolved in acetone (200 uL) and 4M HC1 (500 uL) and stirred for 1 h at 70 °C (Scheme lb). After completion of the reaction, the solution was neutralized with 4M NaOH and the product was purified by semipreparative HPLC.
  • CD spectra of 65 * - and 6i?-5-MTHF and the two reference compounds 6R- and 6S-3'-aza- 2'-fluoro-5-MTHF (6R-1 and 6S-1) were recorded ( Figures 2A and 2B). Opposite spectra were obtained for the two corresponding 6R- and eS-diasteroisomers of each of the two pairs of folates.
  • the spectra of the 65 * - and 6i?-5-MTHF served as reference spectra, since the stereochemistry of these two substances was known. It is reported in the literature that the pterin shows a typical absorption band at around 345 nm and a second band at 280 nm.
  • Radiosyntheses of 6S- and 6i?-3'-aza-2'-[ 18 F]fluoro-5-MTHF were performed in analogy to the radiosynthesis of 3'-aza-2'-[ 18 F]fluorofolic acid previously described in literature (Betzel et al, (2013) Radiosynthesis and Preclinical Evaluation of 3 ' -Aza-2 ' -[18F]fluorofolic Acid: A Novel PET Radiotracer for Folate Receptor Targeting. Bioconjug. Chem.
  • the reaction mixture was allowed to cool down for 2 min and 10 mM sodium phosphate buffer pH 7.4 containing 50 mg/mL of Na-(+)-L-ascorbate (2.5 mL) and 4M NaOH (1.0 mL) were added for stabilizing the product and for neutralizing the acidic solution, respectively.
  • Purification of the product was achieved by semipreparative radio-HPLC.
  • the product fraction was collected and passed through a steril filter into a sterile and pyrogen- free vial. Quality control of 6R- or 65 * -[ 18 F] l was performed on an analytical radio-HPLC. At the end of synthesis, 350-1600 MBq (1-5% d.c. yield) of the final radiotracers were obtained. SA ranged from 46-250 GBq/ ⁇ and radiochemical purity was greater 95%.
  • Analytical radio-HPLC was performed using 50 mM NaH 2 P0 4 (pH 6.5) (solvent A) and 30% MeCN in 50 mM NaH 2 P0 4 (pH 8.0) (solvent B) as a solvent system with a gradient from 0 - 14 min: 100 - 45% A, 14 - 17 min: 45 - 0% A, 17 - 25 min: 0% A, 25 - 26 min: 0 - 100 % A, 26 - 32 min: 100% A, and a flow rate of 1 mL/min (280 nm).
  • Values represent the mean ⁇ standard deviation of sextuples from two independent experiments.
  • Table 1 Overview of the LogD 7 .4 values of the folates and pteroates.
  • the binding affinities of the non-radioactive reference compounds 6R- ⁇ and 6S- 1 were determined using KB cells in a displacement assay with [ 3 H] folic acid.
  • the results (Table 2) showed that the two reference diastereoisomers 6R-1 and 6S- 1 have similar high affinities to the FR-a and are similar to the values of 6S- and 6i?-5-MTHFs.
  • the IC50 value for folic acid under the same experimental conditions was found to be 0.6 + 0.1 nM, whereas 3'-aza-2'- [ 18 F]fluorofolic acid exhibited an IC50 value of 1.4 + 0.5 nM.
  • the corresponding reduced aza- folate derivatives, 6R-1 and 6S-1 show about 17-fold lower affinity to the FR-a.
  • the folate radiotracer 6S/6i?-[ 18 F]5 (1 : 1 ratio, 53.7-52.3 MBq; ⁇ 0.62-1.15 nmol) were intravenously injected into mice in order to determine the in vivo stability of the tracers.
  • Mice were sacrificed 60 min post injection of the tracer and blood, urine and liver were collected and analyzed. Ice-cold methanol containing 10 mg/mL 2-mercaptoethanol and 0.025% (v/v) ammonium hydroxide was added to the blood plasma, homogenized liver and urine in order to precipitate the proteins. 6 After centrifugation, the supernatants of the blood plasma, liver and urine samples were analyzed by radio-UPLC ( Figure 4). The analysis of the samples revealed only intact parent tracer 65 * /6i?-[ 18 F]l 60 min after radiotracer injection.
  • Example 10 In Vivo Investigations of 18 F-Based Reduced Folates: 6R-3'-aza-2'- [ 18 F]fluoro-5-MTHF (6R-[ 18 F] 1) and 6R-3'-aza-2'-[ 18 F]fluoro-5-MTHF (6S-[ 18 F] 1)
  • This value is approximately twice the amount of radioactivity accumulation obtained from the oxidized tracer 3'-aza-2'-[ 18 F]fluorofolic acid (12.59 ⁇ 1.77 % IA/g). Tumor uptake was efficiently blocked by pre-injection of folic acid. Specificity of tumor binding was 85%> and 89%> for the R- and eS-isomers, respectively. A significant higher amount of radioactivity was found in the liver for the 6R -tracer (14.3 ⁇ 1.36% IA/g) compared to the 65 * -tracer (8.10 ⁇ 1.16% IA/g) 30 min p.i..
  • kidney uptake was considerably higher for 65 * -[ 18 F]l compared to the 6i?-[ 18 F]l at 30 min p.i. (6i?-form: 34.5 ⁇ 2.45% IA/g, 65 * -form: 42.5 ⁇ 2.73% IA/g) and remained nearly constant over time for both diastereoisomers (90 min p.i.: 6i?-form: 29.8 ⁇ 7.46% IA/g, 65 * -form: 42.3 ⁇ 7.05% IA/g).
  • both values were considerably lower compared to 3'-aza-2'-[ 18 F]fluorofolic acid (57.3 ⁇ 8.40 % IA/g).
  • Tumor-to-kidney ratio was significantly lower for 65 * -[ 18 F]l (30 min p.i.: 0.26 ⁇ 0.01% IA/g) and increased by a factor of 1.7 to a value of 0.45 ⁇ 0.07% IA/g at 90 min p.i. ( Figure 6).
  • the tumor-to-kidney ratio of 6i?-[ 18 F]l was already 0.39 ⁇ 0.05% IA/g at 30 min p.i. and increased by a factor of 2.1 to 0.83 ⁇ 0.17% IA/g at 90 min p.i..
  • Tumor-to-kidney ratio of 6i?-[ 18 F]l therefore is approximately two- and four-fold higher compared to 65 * -[ 18 F]l and 3'-aza-2'-[ 18 F]fluorofolic acid, respectively.
  • Tumor-to-liver ratio was higher for the eS-isomer compared to the 6i?-isomer at all investigated time points due to the lower liver uptake of 6S-[ 18 F]1. So at 90 min p.i.
  • PET/CT mages maximal intensity projections (MIPs)
  • MIPs maximal intensity projections
  • Radioactivity accumulation in the liver was mainly observed for the 6i?-isomer, however, after 3 h p.i. liver uptake was only barely visible. FR-positive kidneys were clearly visualized 1 h p.i. with 6i?-[ 18 F]l, but nearly invisible at 3 h p.i.. In contrast, high kidney accumulation was observed for 65 * -[ 18 F]l at all investigated time points. Furthermore, high radioactivity uptake was evident in the salivary glands.
  • Blocking studies were performed by injecting folic acid 10 minutes prior to the administration of the radiotracers and resulted in a remarkably reduced uptake of 6i?-[ 18 F]l and 65 * -[ 18 F]l in all FR-positive tissues (KB tumor xenografts, kidneys, salivary glands and choroid plexus) ( Figure 15 and Figure 17).
  • the 65 * - isomer is excreted preferably via the renal pathway, whereas the 6i?-isomer seems to be excreted mainly via the hepatobiliary pathway.
  • Example 12 Cell Uptake and Internalization studies were performed with FR-a and FR- ⁇ transfected CHO cells referred to as RT16 and D4 cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des produits radiopharmaceutiques de (6S)-méthyltétrahydrofolate ou de (6R)-5-méthyltétrahydrofolate isomériquement purs marqués au 18F, le groupe phényle à l'intérieur de la structure de folate ayant été remplacé par un N-hétérocycle marqué au 18F, destinés à être utilisés dans l'imagerie diagnostique d'une cellule ou d'une population de cellules exprimant un récepteur de folate in vitro ou in vivo ou pour une utilisation dans la surveillance du cancer ou de maladies inflammatoires et auto-immunes et leur thérapie.
EP18710887.3A 2017-03-20 2018-03-19 Tétrahydrofolates isomériquement purs marqués au 18f Active EP3601288B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL18710887T PL3601288T3 (pl) 2017-03-20 2018-03-19 Izomerycznie czyste tetrahydrofoliany znakowane 18f

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17161884 2017-03-20
PCT/EP2018/056806 WO2018172243A1 (fr) 2017-03-20 2018-03-19 Tétrahydrofolates isomériquement purs marqués au 18f

Publications (2)

Publication Number Publication Date
EP3601288A1 true EP3601288A1 (fr) 2020-02-05
EP3601288B1 EP3601288B1 (fr) 2021-04-21

Family

ID=58387756

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18710887.3A Active EP3601288B1 (fr) 2017-03-20 2018-03-19 Tétrahydrofolates isomériquement purs marqués au 18f

Country Status (16)

Country Link
US (1) US20200306390A1 (fr)
EP (1) EP3601288B1 (fr)
JP (1) JP7204662B2 (fr)
KR (1) KR102648945B1 (fr)
CN (1) CN110431141B (fr)
AU (1) AU2018237784B2 (fr)
CA (1) CA3057042A1 (fr)
DK (1) DK3601288T3 (fr)
EA (1) EA201992180A1 (fr)
ES (1) ES2893303T3 (fr)
IL (1) IL269059B (fr)
PL (1) PL3601288T3 (fr)
PT (1) PT3601288T (fr)
SG (1) SG11201908679QA (fr)
WO (1) WO2018172243A1 (fr)
ZA (1) ZA201906877B (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008237934B2 (en) 2007-04-11 2014-03-27 Merck & Cie 18F-labelled folates
PT2254890E (pt) * 2008-02-20 2015-07-31 Gnosis Spa Processo para a resolução diastereoisomérica do ácido 5- metiltetra-hidrofólico
US20130034496A1 (en) * 2011-08-04 2013-02-07 University Of Iowa Research Foundation Positron emission tomography tracer
AU2013258027B2 (en) 2012-05-08 2017-11-30 Merck & Cie 18F-labelled follate/antifolate analogues

Also Published As

Publication number Publication date
IL269059B (en) 2021-12-01
DK3601288T3 (da) 2021-07-05
SG11201908679QA (en) 2019-10-30
ZA201906877B (en) 2021-06-30
US20200306390A1 (en) 2020-10-01
EA201992180A1 (ru) 2020-04-23
WO2018172243A1 (fr) 2018-09-27
KR20190130607A (ko) 2019-11-22
PT3601288T (pt) 2021-07-20
JP7204662B2 (ja) 2023-01-16
AU2018237784A1 (en) 2019-11-07
JP2020511477A (ja) 2020-04-16
CN110431141A (zh) 2019-11-08
AU2018237784B2 (en) 2022-04-21
KR102648945B1 (ko) 2024-03-18
IL269059A (en) 2019-11-28
CA3057042A1 (fr) 2018-09-27
PL3601288T3 (pl) 2021-11-08
CN110431141B (zh) 2022-12-30
ES2893303T3 (es) 2022-02-08
EP3601288B1 (fr) 2021-04-21

Similar Documents

Publication Publication Date Title
CN107382846B (zh) Psma-结合剂及其用途
ES2953196T3 (es) Radiotrazador de modo dual de unión a PSMA y terapéutico
JP5595903B2 (ja) １８ｆ標識葉酸
KR20150092700A (ko) 방사성―약제 복합체
Zhou et al. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation
KR20120130769A (ko) 토륨 방사성 핵종 및 히드록시피리디논 함유 리간드를 포함하는 표적화된 알파-입자 방출 복합체
JPH07504661A (ja) 放射免疫イメージング及び放射免疫療法に関するビオチン及びデフェロキサミンのコンジュゲート
JP2019520328A (ja) Ｐｅｔイメージング用免疫修飾因子
WO2005087275A2 (fr) Agents d'imagerie tep radiomarques metalliques
KR20140052027A (ko) 알부민-결합 개체들의 폴레이트 공액체들
Berdal et al. Investigation on the reactivity of nucleophilic radiohalogens with arylboronic acids in water: access to an efficient single-step method for the radioiodination and astatination of antibodies
Choi et al. Highly efficient method for 125I-radiolabeling of biomolecules using inverse-electron-demand Diels–Alder reaction
AU2006217612A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for PET imaging of EGFR expression in malignant tumors
KR101994327B1 (ko) 18f-당류-폴레이트들
AU2018237784B2 (en) Isomerically pure 18F-labelled tetrahydrofolates
Uppal et al. Design, synthesis and biological evaluation of choline based SPECT imaging agent: Ga (III)-DO3A-EA-Choline
Panwar et al. 99mTc-Tetraethylenepentamine-folate a new 99mTc based folate derivative for the detection of folate receptor positive tumors: synthesis and biological evaluation
Wang et al. Radiosynthesis and First Preclinical Evaluation of the Novel 11C-Labeled FAP Inhibitor 11C-FAPI: A Comparative Study of 11C-FAPIs and (68Ga) Ga-DOTA-FAPI-04 in a High–FAP-Expression Mouse Model
WO1992011039A1 (fr) Agents de chelation a base de tricatechol derives
US20080085237A1 (en) Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia
CN113368264B (zh) 放射性标记肉桂霉素，其制备方法及其用途
Lamba et al. Synthetic 18 F labeled biomolecules that are selective and promising for PET imaging: Major advances and applications
Taki Novel Imaging and Therapy Approaches for the Management of Prostate Cancer
Boss Synthesis and Evaluation of Novel Folate Tracers for Tumor Imaging Using PET
WO2020045638A1 (fr) Composé dérivé d'imidazothiadiazole radioactif

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190913

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20201111

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018015856

Country of ref document: DE

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1384516

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210515

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210701

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3601288

Country of ref document: PT

Date of ref document: 20210720

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20210715

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20210421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210721

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210722

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210821

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018015856

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2893303

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20220208

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210821

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220319

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1384516

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210421

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230519

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230404

Year of fee payment: 6

Ref country code: CH

Payment date: 20230401

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20231219

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240108

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240103

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240226

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231229

Year of fee payment: 7

Ref country code: PT

Payment date: 20240318

Year of fee payment: 7

Ref country code: GB

Payment date: 20240108

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20180319

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240219

Year of fee payment: 7

Ref country code: SE

Payment date: 20240103

Year of fee payment: 7

Ref country code: PL

Payment date: 20240115

Year of fee payment: 7

Ref country code: NO

Payment date: 20240222

Year of fee payment: 7

Ref country code: IT

Payment date: 20240212

Year of fee payment: 7

Ref country code: FR

Payment date: 20240103

Year of fee payment: 7

Ref country code: DK

Payment date: 20240314

Year of fee payment: 7

Ref country code: BE

Payment date: 20240105

Year of fee payment: 7